Uppsala, Sweden, November 6. 2017. The Facebook Group " Aktier – Småbolagsjakten " organizes a live QA session with Biovica International's CEO Anders Rylander on November 20, 2017 between 19.00 - 20.00.
Biovica's CEO Anders Rylander summarizes the first quarter of the company's fiscal year 2017/18. The interview focuses on the latest recruitments that have been made during the quarter, the DiviTum technology, and regulatory approvals needed for the product in key markets. The interview ends with Anders Rylander commenting on the Biovica strategy until 2019. [...]
Uppsala, Sweden, May 22 2017. Samuel Rotstein has been appointed as Scientific Advisor to Biovica.
Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]
Uppsala, Sweden, May 4 2017. Biovica has received an order for the company's product DiviTum® from a global contract research company (CRO company), commissioned by a global pharmaceutical company to study the effectiveness of new cancer drugs.
Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]
Lund University includes DiviTum® in study for treatment efficacy evaluation of breast cancer patients
Lund University select Biovicas DiviTum® assay for inclusion in a study of 150 women with metastatic breast cancer. The purpose of the study is faster evaluation of treatment efficacy than current standard methods. Lund University will buy about 550 DiviTum tests.
Biovica will participate in a EUROSTAR research project called SUBLYME, that will develop a new targeted drug for blood cancer. For Biovica the project expand the application of DiviTum® to one of the most common forms of blood cancer where the incidence has doubled in the past decades.
Biovica CEO Anders Rylander is interviewed by the results presented at the AACR conference 1-5 April 2017. Read the interview here.
Uppsala, Sweden, April 3 2017. The latest data of the DiviTum® assay as an efficacy marker of CDK4/6 inhibition was presented in an oral session by Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, at the 2017 American Association for Cancer Research (AACR) Annual Meeting.